OpenURL Connection Search

Select item for more details and to access through your institution.

Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis*.
Published in:
British Journal of Dermatology, 2022, v. 186, n. 3, p. 466, doi. 10.1111/bjd.20818
By:
- Gordon, K.B.;
- Lebwohl, M.;
- Papp, K.A.;
- Bachelez, H.;
- Wu, J.J.;
- Langley, R.G.;
- Blauvelt, A.;
- Kaplan, B.;
- Shah, M.;
- Zhao, Y.;
- Sinvhal, R.;
- Reich, K.
Publication type:
Article
Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*.
Published in:
British Journal of Dermatology, 2021, v. 185, n. 2, p. 323, doi. 10.1111/bjd.19866
By:
- Thaci, D.;
- Piaserico, S.;
- Warren, R.B.;
- Gupta, A.K.;
- Cantrell, W.;
- Draelos, Z.;
- Foley, P.;
- Igarashi, A.;
- Langley, R.G.;
- Asahina, A.;
- Young, M.;
- Falqués, M.;
- Pau‐Charles, I.;
- Mendelsohn, A.M.;
- Rozzo, S.J.;
- Reich, K.
Publication type:
Article
A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial.
Published in:
British Journal of Dermatology, 2021, v. 184, n. 6, p. 1047, doi. 10.1111/bjd.19509
By:
- Blauvelt, A.;
- Leonardi, C.;
- Elewski, B.;
- Crowley, J.J.;
- Guenther, L.C.;
- Gooderham, M.;
- Langley, R.G.;
- Vender, R.;
- Pinter, A.;
- Griffiths, C.E.M.;
- Tada, Y.;
- Elmaraghy, H.;
- Lima, R.G.;
- Gallo, G.;
- Renda, L.;
- Burge, R.;
- Park, S.Y.;
- Zhu, B.;
- Papp, K.
Publication type:
Article
Long‐term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo‐controlled studies.
Published in:
British Journal of Dermatology, 2021, v. 184, n. 4, p. 640, doi. 10.1111/bjd.19314
By:
- Blauvelt, A.;
- Paul, C.;
- Kerkhof, P.;
- Warren, R.B.;
- Gottlieb, A.B.;
- Langley, R.G.;
- Brock, F.;
- Arendt, C.;
- Boehnlein, M.;
- Lebwohl, M.;
- Reich, K.
Publication type:
Article
Exploring new concepts in the successful management of psoriasis.
Published in:
Journal of the European Academy of Dermatology & Venereology, 2012, v. 26, p. 1, doi. 10.1111/j.1468-3083.2011.04409.x
By:
- Langley, R.G.
Publication type:
Article
Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?
Published in:
Journal of the European Academy of Dermatology & Venereology, 2012, v. 26, p. 21, doi. 10.1111/j.1468-3083.2011.04412.x
By:
- Langley, R.G.
Publication type:
Article
Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus.
Published in:
Journal of the European Academy of Dermatology & Venereology, 2012, v. 26, n. 3, p. 373, doi. 10.1111/j.1468-3083.2011.04349.x
By:
- Langley, R.G.;
- Saurat, J.H.;
- Reich, K.
Publication type:
Article
Super‐response to guselkumab treatment in patients with moderate‐to‐severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance.
Published in:
Journal of the European Academy of Dermatology & Venereology, 2022, v. 36, n. 12, p. 2393, doi. 10.1111/jdv.18474
By:
- Reich, K.;
- Gordon, K.B.;
- Strober, B.;
- Langley, R.G.;
- Miller, M.;
- Yang, Y.‐W.;
- Shen, Y.‐K.;
- You, Y.;
- Zhu, Y.;
- Foley, P.;
- Blauvelt, A.
Publication type:
Article
Use of dose–exposure–response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasis.
Published in:
Journal of the European Academy of Dermatology & Venereology, 2019, v. 33, n. 11, p. 2082, doi. 10.1111/jdv.15668
By:
- Lebwohl, M.;
- Langley, R.G.;
- Zhu, Y.;
- Zhou, H.;
- Song, M.;
- Shen, Y.K.;
- Parnell Lafferty, K.;
- Reich, K.
Publication type:
Article
Secukinumab, a fully human anti‐interleukin‐17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years.
Published in:
Journal of the European Academy of Dermatology & Venereology, 2019, v. 33, n. 9, p. 1733, doi. 10.1111/jdv.15637
By:
- Reich, K.;
- Blauvelt, A.;
- Armstrong, A.;
- Langley, R.G.;
- de Vera, A.;
- Kolbinger, F.;
- Spindeldreher, S.;
- Ren, M.;
- Bruin, G.
Publication type:
Article
Long‐term safety profile of ixekizumab in patients with moderate‐to‐severe plaque psoriasis: an integrated analysis from 11 clinical trials.
Published in:
Journal of the European Academy of Dermatology & Venereology, 2019, v. 33, n. 2, p. 333, doi. 10.1111/jdv.15242
By:
- Langley, R.G.;
- Kimball, A.B.;
- Nak, H.;
- Xu, W.;
- Pangallo, B.;
- Osuntokun, O.O.;
- Agada, N.;
- Reich, K.
Publication type:
Article
Systematic review of the real‐world evidence of adalimumab safety in psoriasis registries.
Published in:
Journal of the European Academy of Dermatology & Venereology, 2018, v. 32, n. 12, p. 2126, doi. 10.1111/jdv.15203
By:
- Strober, B.;
- Crowley, J.;
- Langley, R.G.;
- Gordon, K.;
- Menter, A.;
- Leonardi, C.;
- Arikan, D.;
- Valdecantos, W.C.
Publication type:
Article
Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials ( UNCOVER-1, UNCOVER-2 and UNCOVER-3).
Published in:
Journal of the European Academy of Dermatology & Venereology, 2017, v. 31, n. 10, p. 1686, doi. 10.1111/jdv.14237
By:
- Menter, A.;
- Warren, R.B.;
- Langley, R.G.;
- Merola, J.F.;
- Kerr, L.N.;
- Dennehy, E.B.;
- Shrom, D.;
- Amato, D.;
- Okubo, Y.;
- Reich, K.
Publication type:
Article
Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey.
Published in:
Journal of the European Academy of Dermatology & Venereology, 2015, v. 29, n. 10, p. 2002, doi. 10.1111/jdv.13150
By:
- Kerkhof, P.C.M.;
- Reich, K.;
- Kavanaugh, A.;
- Bachelez, H.;
- Barker, J.;
- Girolomoni, G.;
- Langley, R.G.;
- Paul, C.F.;
- Puig, L.;
- Lebwohl, M.G.
Publication type:
Article
Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis.
Published in:
Journal of the European Academy of Dermatology & Venereology, 2015, v. 29, n. 9, p. 1763, doi. 10.1111/jdv.12996
By:
- Langley, R.G.;
- Rich, P.;
- Menter, A.;
- Krueger, G.;
- Goldblum, O.;
- Dutronc, Y.;
- Zhu, B.;
- Wei, H.;
- Cameron, G.S.;
- Heffernan, M.P.
Publication type:
Article
Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar ( PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial.
Published in:
Journal of the European Academy of Dermatology & Venereology, 2014, v. 28, n. 10, p. 1298, doi. 10.1111/jdv.12272
By:
- Bissonnette, R.;
- Nigen, S.;
- Langley, R.G.;
- Lynde, C.W.;
- Tan, J.;
- Fuentes ‐ Duculan, J.;
- Krueger, J.G.
Publication type:
Article
Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH.
Published in:
Journal of the European Academy of Dermatology & Venereology, 2014, v. 28, n. 7, p. 882, doi. 10.1111/jdv.12198
By:
- Poulin, Y.;
- Crowley, J.J.;
- Langley, R.G.;
- Unnebrink, K.;
- Goldblum, O.M.;
- Valdecantos, W.C.
Publication type:
Article
Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis.
Published in:
Journal of the European Academy of Dermatology & Venereology, 2013, v. 27, n. 10, p. 1252, doi. 10.1111/j.1468-3083.2012.04705.x
By:
- Langley, R.G.;
- Papp, K.;
- Gottlieb, A.B.;
- Krueger, G.G.;
- Gordon, K. B.;
- Williams, D.;
- Valdes, J.;
- Setze, C.;
- Strober, B.
Publication type:
Article
A study comparing the biologic drugs ixekizumab and guselkumab for the treatment of moderate‐to‐severe plaque psoriasis.
Published in:
British Journal of Dermatology, 2020, v. 182, n. 6, p. e193, doi. 10.1111/bjd.19072
By:
- Blauvelt, A.;
- Papp, K.;
- Gottlieb, A.;
- Jarell, A.;
- Reich, K.;
- Maari, C.;
- Gordon, K.B.;
- Ferris, L.K.;
- Langley, R.G.;
- Tada, Y.;
- Lima, R.G.;
- Elmaraghy, H.;
- Gallo, G.;
- Renda, L.;
- Park, S.Y.;
- Burge, R.;
- Bagel, J.
Publication type:
Article
生物药物 ixekizumab 和 guselkumab 治疗中度至重度斑块型银屑病的比较研究.
Published in:
British Journal of Dermatology, 2020, v. 182, n. 6, p. e205, doi. 10.1111/bjd.19084
By:
- Blauvelt, A.;
- Papp, K.;
- Gottlieb, A.;
- Jarell, A.;
- Reich, K.;
- Maari, C.;
- Gordon, K.B.;
- Ferris, L.K.;
- Langley, R.G.;
- Tada, Y.;
- Lima, R.G.;
- Elmaraghy, H.;
- Gallo, G.;
- Renda, L.;
- Park, S.Y.;
- Burge, R.;
- Bagel, J.
Publication type:
Article
A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial.
Published in:
British Journal of Dermatology, 2020, v. 182, n. 6, p. 1348, doi. 10.1111/bjd.18851
By:
- Blauvelt, A.;
- Papp, K.;
- Gottlieb, A.;
- Jarell, A.;
- Reich, K.;
- Maari, C.;
- Gordon, K.B.;
- Ferris, L.K.;
- Langley, R.G.;
- Tada, Y.;
- Lima, R.G.;
- Elmaraghy, H.;
- Gallo, G.;
- Renda, L.;
- Park, S.Y.;
- Burge, R.;
- Bagel, J.;
- Vender, Ronald;
- Lomaga, Mark A.;
- Delorme, Isabelle
Publication type:
Article
Brodalumab 用于对乌司奴单抗应答不足的患者.
Published in:
British Journal of Dermatology, 2019, v. 180, n. 2, p. e53, doi. 10.1111/bjd.17484
By:
- Langley, R.G.;
- Armstrongi, A.W.;
- Lebwohl, M.G.;
- Blauvelt, A.;
- Hsu, S.;
- Tyring, S.;
- Rastogi, S.;
- Pillai, R.;
- Israel, R.
Publication type:
Article
Brodalumab in patients who had inadequate response to ustekinumab.
Published in:
British Journal of Dermatology, 2019, v. 180, n. 2, p. e40, doi. 10.1111/bjd.17471
By:
- Langley, R.G.;
- Armstrongi, A.W.;
- Lebwohl, M.G.;
- Blauvelt, A.;
- Hsu, S.;
- Tyring, S.;
- Rastogi, S.;
- Pillai, R.;
- Israel, R.
Publication type:
Article
Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials.
Published in:
British Journal of Dermatology, 2019, v. 180, n. 2, p. 306, doi. 10.1111/bjd.17318
By:
- Langley, R.G.;
- Armstrong, A.W.;
- Lebwohl, M.G.;
- Blauvelt, A.;
- Hsu, S.;
- Tyring, S.;
- Rastogi, S.;
- Pillai, R.;
- Israel, R.
Publication type:
Article
Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database.
Published in:
British Journal of Dermatology, 2018, v. 179, n. 5, p. 1205, doi. 10.1111/bjd.16901
By:
- Warren, R.B.;
- Reich, K.;
- Langley, R.G.;
- Strober, B.;
- Gladman, D.;
- Deodhar, A.;
- Bachhuber, T.;
- Bao, W.;
- Altemeyer, E.;
- Hussain, S.;
- Safi, J.
Publication type:
Article
Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.
Published in:
British Journal of Dermatology, 2017, v. 176, n. 3, p. 752, doi. 10.1111/bjd.14965
By:
- Reich, K.;
- Blauvelt, A.;
- Armstrong, A.;
- Langley, R.G.;
- Fox, T.;
- Huang, J.;
- Papavassilis, C.;
- Liang, E.;
- Lloyd, P.;
- Bruin, G.
Publication type:
Article
A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.
Published in:
British Journal of Dermatology, 2016, v. 175, n. 2, p. 273, doi. 10.1111/bjd.14493
By:
- Papp, K.A.;
- Reich, K.;
- Paul, C.;
- Blauvelt, A.;
- Baran, W.;
- Bolduc, C.;
- Toth, D.;
- Langley, R.G.;
- Cather, J.;
- Gottlieb, A.B.;
- Thaçi, D.;
- Krueger, J.G.;
- Russell, C.B.;
- Milmont, C.E.;
- Li, J.;
- Klekotka, P.A.;
- Kricorian, G.;
- Nirula, A.
Publication type:
Article
Tildrakizumab ( MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
Published in:
British Journal of Dermatology, 2015, v. 173, n. 4, p. 930, doi. 10.1111/bjd.13932
By:
- Papp, K.;
- Thaçi, D.;
- Reich, K.;
- Riedl, E.;
- Langley, R.G.;
- Krueger, J.G.;
- Gottlieb, A.B.;
- Nakagawa, H.;
- Bowman, E.P.;
- Mehta, A.;
- Li, Q.;
- Zhou, Y.;
- Shames, R.
Publication type:
Article
Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up.
Published in:
British Journal of Dermatology, 2015, v. 172, n. 5, p. 1371, doi. 10.1111/bjd.13469
By:
- Langley, R.G.;
- Lebwohl, M.;
- Krueger, G.G.;
- Szapary, P.O.;
- Wasfi, Y.;
- Chan, D.;
- Hsu, M.C.;
- You, Y.;
- Poulin, Y.;
- Korman, N.;
- Prinz, J.C.;
- Reich, K.
Publication type:
Article
The interpretation of long-term trials of biologic treatments for psoriasis: trial designs and the choices of statistical analyses affect ability to compare outcomes across trials.
Published in:
British Journal of Dermatology, 2013, v. 169, n. 6, p. 1198, doi. 10.1111/bjd.12583
By:
- Langley, R.G.;
- Reich, K.
Publication type:
Article
Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment.
Published in:
British Journal of Dermatology, 2013, v. 169, n. 5, p. 992, doi. 10.1111/bjd.12517
By:
- Strober, B.;
- Buonanno, M.;
- Clark, J.D.;
- Kawabata, T.;
- Tan, H.;
- Wolk, R.;
- Valdez, H.;
- Langley, R.G.;
- Harness, J.;
- Menter, A.;
- Papp, K.
Publication type:
Article
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
Published in:
British Journal of Dermatology, 2013, v. 168, n. 2, p. 412, doi. 10.1111/bjd.12110
By:
- Papp, K.A.;
- Langley, R.G.;
- Sigurgeirsson, B.;
- Abe, M.;
- Baker, D.R.;
- Konno, P.;
- Haemmerle, S.;
- Thurston, H.J.;
- Papavassilis, C.;
- Richards, H.B.
Publication type:
Article
A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis.
Published in:
British Journal of Dermatology, 2012, v. 167, n. 3, p. 649, doi. 10.1111/j.1365-2133.2012.11015.x
By:
- Gottlieb, A.B.;
- Langley, R.G.;
- Strober, B.E.;
- Papp, K.A.;
- Klekotka, P.;
- Creamer, K.;
- Thompson, E.H.Z.;
- Hooper, M.;
- Kricorian, G.
Publication type:
Article
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.
Published in:
British Journal of Dermatology, 2012, v. 167, n. 3, p. 668, doi. 10.1111/j.1365-2133.2012.11168.x
By:
- Papp, K.A.;
- Menter, A.;
- Strober, B.;
- Langley, R.G.;
- Buonanno, M.;
- Wolk, R.;
- Gupta, P.;
- Krishnaswami, S.;
- Tan, H.;
- Harness, J.A.
Publication type:
Article
Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study.
Published in:
British Journal of Dermatology, 2011, v. 165, n. 2, p. 399, doi. 10.1111/j.1365-2133.2011.10399.x
By:
- Saurat, J.-H.;
- Langley, R.G.;
- Reich, K.;
- Unnebrink, K.;
- Sasso, E.H.;
- Kampman, W.
Publication type:
Article
Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.
Published in:
British Journal of Dermatology, 2011, v. 164, n. 2, p. 434, doi. 10.1111/j.1365-2133.2010.10139.x
By:
- Papp, K.;
- Crowley, J.;
- Ortonne, J.-P.;
- Leu, J.;
- Okun, M.;
- Gupta, S.R.;
- Gu, Y.;
- Langley, R.G.
Publication type:
Article

Found: 36